US Patent 9,572,814 (Doxepin for Insomnia): Scope, Claims, and U.S. Patent Landscape
What does US 9,572,814 claim and how broad is the coverage?
US 9,572,814 claims method-of-treatment regimens for insomnia using doxepin with two key dosing-context constraints:
1) Dose range windows
- Claim 1: administer 0.5 mg to 7 mg doxepin
- Claim 8: administer 1 mg to 6 mg doxepin (sleep maintenance insomnia)
2) Timing relative to sleep and food
- Claim 1: administer doxepin before bedtime and at least 3 hours after consuming a meal
- Claim 8: administer doxepin within about 1 hour before bedtime and at least 3 hours after consuming a meal
3) Purpose statements embedded as functional outcomes
Both independent claims state the regimen “thereby” provides:
- faster onset of action, and
- reducing next-day residual effects.
While these “thereby” phrases can be used to support interpretation of what the regimen is supposed to achieve, the enforceable hook is still the combination of dose + timing + food separation.
Independent claim scope snapshot
| Feature |
Claim 1 (insomnia) |
Claim 8 (sleep maintenance insomnia) |
| Indication |
Insomnia |
Sleep maintenance insomnia |
| Dose range |
0.5 mg to 7 mg |
1 mg to 6 mg |
| Bedtime timing |
“Before bedtime” |
“Within about 1 hour before bedtime” |
| Food separation |
At least 3 hours after a meal |
At least 3 hours after a meal |
| Oral timing precision |
Low (open-ended “before bedtime”) |
Higher (bounded by ~1 hour) |
| Pharmacokinetic-dependent dependent claim |
Not in independent |
Claims 12-14 tie to Tmax/Cmax/AUC vs high-fat meal |
How do the dependent claims narrow or differentiate the regimen?
Dose-strength fallbacks
The patent includes explicit narrow embodiments that can matter for design-around analysis:
- Claim 2: about 3 mg (depends on claim 1)
- Claim 3: about 6 mg (depends on claim 1)
- Claim 9: about 3 mg (depends on claim 8)
- Claim 10: about 6 mg (depends on claim 8)
Dosage form and administration format
The regimen is not confined to one solid form:
- Claim 4: tablet, capsule, or liquid (depends on claim 1)
- Claim 5: unit dosage form (depends on claim 1)
- Claim 6: oral dosage form (depends on claim 1)
- Claim 11: tablet, capsule, or liquid (depends on claim 8)
These dependencies restrict the infringement theory toward oral administration within those formats, but they do not lock in a particular excipient profile or release mechanism in the text you provided.
Bedtime timing constraint
- Claim 7: administer within about 1 hour of bedtime (depends on claim 1)
This narrows claim 1’s “before bedtime” to a more specific therapeutic window.
Pharmacokinetic comparisons (high-fat meal reference)
Claims 12-14 create a PK-based differentiation in the sleep maintenance insomnia pathway:
- Claim 12: method shortens median Tmax vs high fat meal
- Claim 13: decreases Cmax vs high fat meal
- Claim 14: decreases AUC vs high fat meal
These claims support a narrative that food separation changes absorption kinetics and exposure, tying the regimen to measurable PK outcomes. Practically, they also provide evidentiary hooks if infringement is contested on whether a given patient’s regimen “works” in the intended way.
Where is the legal “center of gravity” for infringement risk?
For method-of-treatment patents, the most operational infringement risk usually sits in what providers and patients do: the administered amount and the timing relative to meals and bedtime.
The strongest infringement vectors are:
1) Patients taking low-dose doxepin for insomnia (0.5 to 7 mg) under a label-like instruction to avoid food timing issues.
2) Clinicians or studies instructing “at least 3 hours after a meal” and timing it close to bedtime (especially for sleep maintenance insomnia, where claim 8 locks “within about 1 hour before bedtime”).
3) PK outcomes vs high-fat meal if a challenger disputes “faster onset” and “residual effects” and the patent asserts specific Tmax/Cmax/AUC directions.
What design-arounds are suggested by the claim boundaries?
Based strictly on the claim language you provided, the main “levers” are the dose boundaries and the timing boundaries.
Dose levers
- Claim 1 covers 0.5 mg to 7 mg. Avoiding the claimed range by using below 0.5 mg or above 7 mg is a direct way to miss claim scope (but you would still need to consider other patents and label constraints).
- Claim 8 covers 1 mg to 6 mg. Using below 1 mg or above 6 mg is a direct miss for that independent claim.
Food separation lever
Both independent claims require at least 3 hours after consuming a meal.
- Using < 3 hours after a meal can fall outside the express limitation.
- Using no meal constraint is also a path to non-infringement, but in practice it would likely affect PK and outcomes.
Bedtime timing lever
- Claim 1: “before bedtime” (broad)
- Claim 8: “within about one hour before bedtime” (narrower)
- Claim 7: “within about one hour of bedtime” (narrower)
If a regimen is intentionally spread farther from bedtime, it may better avoid claim 8 and claim 7, while still being within claim 1’s broader “before bedtime” wording.
How does the patent likely sit inside the broader doxepin insomnia landscape?
This patent is drafted as a process/regimen patent. In the doxepin-insomnia ecosystem, that typically coexists with:
- product-related IP (composition/formulation and manufacturing)
- use/patient selection IP (specific dosing schedules, timing constraints, and outcome-linked PK behaviors)
- regulatory-label protected instructions (methods and instructions that can align with claim elements)
The particular novelty claimed here is the combination of:
- low-dose doxepin in a narrow milligram range, with
- food separation at least 3 hours, plus
- close-to-bed administration and
- directional PK outcomes when compared to high-fat meal dosing.
That profile is the kind of IP that can matter even where the active is old, because the claims focus on how to take a known drug to change absorption kinetics and next-day exposure.
Claim-to-landscape mapping: what parties will care about
Commercial incumbents and generic entrants
- Brand/labeled dosing that includes “avoid food” or “3 hours after meals” can increase infringement exposure for any regimen that fits claim 1 or claim 8.
- Generic products are not automatically shielded if the label or patient instructions induce the claimed method. A regimen patent can still be asserted if the generic is used according to the claimed timing and dose.
Clinical investigators
- Trial protocols that specify exact dosing windows and meal restrictions can align tightly with the claimed elements.
- PK study designs comparing high-fat vs fasting dosing can be relevant to claims 12-14.
Investors and licensing strategists
- A process patent can be licensed or asserted in segments. Here, the most licenseable “deal terms” would likely be tied to authorized patient instructions and dosing regimens that mirror the claim constraints.
What is the likely evidentiary path if the claims are challenged?
Claims 12-14 create an objective comparison frame (high-fat meal comparator). If a dispute arises over:
- what “faster onset” means, or
- whether residual effects are reduced,
then the patent text’s PK directional language supplies litigation-friendly comparators (Tmax/Cmax/AUC). That does not eliminate the need for experts, but it narrows the space: the claim language already pushes toward measurable parameters.
Where does the coverage appear most vulnerable (claim construction risk)?
Without the full specification and prosecution history, the claim-level risks to a patentee typically cluster around:
- “about” tolerances for 0.5 to 7 mg and for 3 mg and 6 mg (how “about” is construed can expand or contract scope).
- “at least 3 hours after consuming a meal”: what counts as a “meal,” what counts as “consuming,” and whether partial nutrition qualifies.
- “within about one hour”: again, “about” can swing scope.
- Functional “thereby” language: a defendant may argue non-correlation to clinical outcomes, though PK-dependent claims help.
Scope summary: the actionable claim set
Core regimen (most important elements)
- Low-dose doxepin
- Administer close to bedtime
- Ensure at least 3 hours has elapsed after consuming a meal
Important dependent refinements
- Specific dose strengths: ~3 mg, ~6 mg
- Oral formats: tablet/capsule/liquid and unit dosage
- Tight bedtime timing: within about 1 hour
- PK directionality vs high-fat meal: shorter Tmax, lower Cmax, lower AUC
Key Takeaways
- US 9,572,814 covers method-of-treatment regimens for insomnia and sleep maintenance insomnia using low-dose doxepin with two operational constraints: timing to bedtime and meal separation of at least 3 hours.
- The patent’s enforceable scope centers on dose range + administration timing + after-meal restriction; dependent claims lock in ~3 mg and ~6 mg and specify oral unit dosage formats.
- Claims 12-14 introduce objective PK comparator language versus a high-fat meal, strengthening the evidentiary basis for “faster onset” and reduced exposure.
- For design-around planning, the most direct levers are avoiding the dose ranges or breaking the 3-hour post-meal limitation, with bedtime timing also affecting whether claim 8/7 are implicated.
FAQs
1) Is this patent about doxepin formulation or dosing instructions?
It is drafted as a method of treating insomnia/sleep maintenance insomnia, focusing on how and when to administer doxepin (dose ranges and timing relative to meals and bedtime).
2) What timing requirement is central to the claims?
Both independent claims require doxepin be given at least 3 hours after consuming a meal.
3) What dose range does claim 1 cover?
Claim 1 covers administration of 0.5 mg to 7 mg doxepin.
4) How does claim 8 differ from claim 1?
Claim 8 narrows the indication to sleep maintenance insomnia and tightens bedtime timing to within about 1 hour before bedtime, while using a 1 mg to 6 mg dose range.
5) Do the claims mention pharmacokinetics?
Yes. Claims 12-14 require that, compared to dosing with a high-fat meal, the regimen shortens median Tmax, decreases Cmax, and decreases AUC.
References
- United States Patent 9,572,814 (claims as provided by user).
